A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates - Wikidata - wikimedia - TriplyDB

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

http://www.wikidata.org/entity/Q27655476

about

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation The PCSK9 decade PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab New developments in atherosclerosis: clinical potential of PCSK9 inhibition Familial hypercholesterolemia: present and future management Profile of evolocumab and its potential in the treatment of hyperlipidemia Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia Improving the predictive value of interventional animal models data A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor PCSK9 inhibitors in the prevention of cardiovascular disease PCSK9 inhibitors - mechanisms of action Retargeting the management of hypercholesterolemia - focus on evolocumab Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Malfolded protein structure and proteostasis in lung diseases.A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective).PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol What lies ahead for the proprotein convertases?Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.Fabs enable single particle cryoEM studies of small proteins Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Proprotein convertases in high-density lipoprotein metabolism.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A cholesterol-lowering VLP vaccine that targets PCSK9 A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.Molecular Validation of PACE4 as a Target in Prostate Cancer PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

P2860

Q21136366-D5393129-E2AC-420F-A08C-824DA97EBC0D Q24294486-65B93FE4-53B1-48AC-A2D0-ED1FC34A2CEA Q24615397-736938E4-903D-4872-96A8-D7A190991E8D Q24633470-175FC2E5-996B-430C-9F02-4D1536E8EC47 Q24658351-833479B5-EFCE-4135-BB7F-E92BC9D24714 Q26747776-AA295440-232C-44F7-AB85-32D5418186D4 Q26783407-712BEB10-4952-48A5-A8D6-4EB396137CEF Q26828489-36578AED-2D48-4615-A671-1EB7BED93472 Q27004235-8EA0E452-0E63-45B1-80D5-45C09E20F3C7 Q27009477-BBE0FAC9-AB5B-4CDC-A753-CE0D48BC76B1 Q27013494-9EF43EAA-E70F-4B50-8E82-F8E7E2BED517 Q27026822-DCF40139-2D09-4CFF-AF05-123A8B43B9A1 Q27665195-E2C1C80F-0522-413C-BA6D-D4CC386A46D0 Q27680601-D5A191ED-BE90-4E3B-B640-66938A0EE3DD Q28071452-7AD2DDD0-38E4-4078-B706-C362ED093687 Q28073987-390355A0-3316-46FE-ABEB-6CFF07532E20 Q28077289-312FF974-7A03-40FB-BD8F-3B444E8ACF09 Q28082561-B5889B8E-EF1D-444C-82C3-611CB03BC78E Q28083595-35700C35-F2D9-4953-B049-F830B6ACFCA8 Q30353585-812FEFF7-492C-475F-A44D-E924D83C94AE Q33532964-9C00684D-0DD1-4491-9E5D-BDB9AB39D9DB Q33577851-07418A13-8586-46F1-BB47-DC60003D08D3 Q33824868-AEC52BBE-D593-4C72-B9DE-D00E9C32B83F Q33904455-7D8C10EB-D4B6-4ECB-A5CB-7F2CDA9EAC44 Q34013439-10C8B571-44D3-460A-841C-E02E58D5C173 Q34053143-0D0D0BED-6A45-4932-B88A-1AFC7E821CD8 Q34169463-AA152720-ECD7-4195-BC22-C048DEB3203F Q34223925-D80EB03C-AEF5-421A-8CCA-28277679EA43 Q34223995-E0C938D8-45C5-48EA-A484-6BE471CCE5AC Q34227474-67BC9AB0-185D-482E-8BBC-C9A952AC478A Q34256139-24189FF1-B0D7-41E3-9F17-3218611918B2 Q34433146-2755C0B3-C9B7-4EEF-84B0-E441DD9677DC Q34458693-2D8E18E5-90F6-4311-86F8-53E268B55F34 Q34496015-9BE87142-3C50-4B7D-8DAB-6A1E977DFD38 Q34568486-D98EB198-9063-440B-A41F-4D05EC636747 Q34662589-C851C097-B51E-4BBA-A448-5952DBD65941 Q34857971-DAD3D391-F0AE-4ABB-BE4C-590CCBEDA6C0 Q34937512-B4BB4739-E9D7-4E69-9FEA-2F976D40C921 Q35015483-D982E62F-813C-4D37-93FF-3117BAE97F73 Q35036348-3368747D-86E0-4312-877B-35DF591EA40D

P2860

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

http://www.wikidata.org/entity/Q27655476

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A proprotein convertase subtil ...... in mice and nonhuman primates

@ast

A proprotein convertase subtil ...... in mice and nonhuman primates

@en

A proprotein convertase subtil ...... in mice and nonhuman primates

@nl

type

label

A proprotein convertase subtil ...... in mice and nonhuman primates

@ast

A proprotein convertase subtil ...... in mice and nonhuman primates

@en

A proprotein convertase subtil ...... in mice and nonhuman primates

@nl

prefLabel

A proprotein convertase subtil ...... in mice and nonhuman primates

@ast

A proprotein convertase subtil ...... in mice and nonhuman primates

@en

A proprotein convertase subtil ...... in mice and nonhuman primates

@nl

P1433

Q27655476-92B7EB68-82FC-4028-9689-A17F1F36911C

P1476

Q27655476-D6D64FB5-8E91-48D7-920D-EA6986970E65

P2093

Q27655476-05843FCA-8D84-461B-B522-D7E2F568680D

Q27655476-08381AF0-30C5-4824-8370-497E84575615

Q27655476-13C10BC9-093D-494D-B2BB-8185AD551592

Q27655476-1C1D7E80-6A36-43B4-961A-D97D64310A5C

Q27655476-1E9764D8-C2D1-4131-8B3D-36437AB7CF73

Q27655476-218FA8A3-7F83-4AFF-BEED-6910805606AB

Q27655476-2762CD09-3F98-4125-B41D-F85C56C78352

Q27655476-2BE46F86-2FF8-44CB-8D6D-9474A6F0C6DA

Q27655476-392D0182-3E1B-4DC8-A5A4-F71F080D386D

Q27655476-3F564242-D525-4212-A19E-5EAB82136241

P2860

Q27655476-02BAD14F-575E-4B1D-86E5-BB9AF9019DF9

Q27655476-02C9AF22-D4AA-4CCA-8FA9-C7EA36D61E1B

Q27655476-0E7D5B1F-37DB-48E3-891A-FD9F3C3ED905

Q27655476-101A5CA7-86E2-49B8-8EF7-22DF8FF0B747

Q27655476-132F68CD-0AED-4AAC-B494-128B4E0A8E43

Q27655476-1C6FAAB5-BFAD-450A-B1F7-CD5BA7FEEC5A

Q27655476-2248A92D-1AA7-4F56-BFC0-AE8779604FD7

Q27655476-2DE2FC7E-6C8F-41B9-931E-8FBAD41A1847

Q27655476-47B1E103-1B8E-4E13-B77A-72161737EDDC

Q27655476-47B5FED7-9347-4363-BFB9-C1126042AD94

P304

Q27655476-2C471EA0-0C44-433A-AC38-9499DBB46EF8

P31

Q27655476-FB73F878-6E32-475E-9B96-9D18772289DB

P3181

Q27655476-9D5465AE-A863-4EA9-968D-212E38DC8D8A

P356

Q27655476-7BCB1C00-6830-4590-A884-B8C784D399E8

P407

Q27655476-9E017791-8BA0-4CC2-A163-CDC27832B9C4

P433

Q27655476-65DE068B-8657-4944-A22E-BFF0D27E7709

P478

Q27655476-3F383053-B887-4112-A98C-4DA2272E3FE5

P577

Q27655476-B3EE55CC-B04F-489A-9A9F-3DD8323C6244

P5875

Q27655476-F9BDAA1F-C14D-4DF6-9C37-2E13E4EBB5D7

P698

Q27655476-2631DA2A-1836-4321-AD8C-D14C69F99C77

P921

Q27655476-26A6F967-1F3B-4B26-9CAD-49C040D5FE77

P932

Q27655476-87EF4C36-7B72-4BC7-95ED-F8831B5DE672

P3181

P356

PNAS.0903849106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A proprotein convertase subtil ...... in mice and nonhuman primates

@en

P2093

Bei Shan

http://www.w3.org/2001/XMLSchema#string

Bryna Fuchslocher

http://www.w3.org/2001/XMLSchema#string

Chadwick King

http://www.w3.org/2001/XMLSchema#string

Derek E Piper

http://www.w3.org/2001/XMLSchema#string

Dongming Liu

http://www.w3.org/2001/XMLSchema#string

Evelyn Yang

http://www.w3.org/2001/XMLSchema#string

Gayle Kwon

http://www.w3.org/2001/XMLSchema#string

Heather Salomonis

http://www.w3.org/2001/XMLSchema#string

Jackie Sheng

http://www.w3.org/2001/XMLSchema#string

Jared Higbee

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

FGF21 N- and C-termini play different roles in receptor interaction and activation

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Continuous cultures of fused cells secreting antibody of predefined specificity

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Processing of X-ray diffraction data collected in oscillation mode

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

P304

9820-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1767678

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0903849106

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24428745

http://www.w3.org/2001/XMLSchema#string

P698

19443683

http://www.w3.org/2001/XMLSchema#string

P921

P932

2682542

http://www.w3.org/2001/XMLSchema#string